Anti-apoptotic therapy is useful in such conditions, and a decrease in the correlation of Bcl-2 and Bcl-XL with obesity suggests decreased anti-apoptosis with obesity. Here, BCL2L1 is linked to obesity due to melanocortin 4 receptor deficiency.